AI Terminal
Trainline PLC
Report Publication Announcement • Jul 6, 2022
5025_rns_2022-07-06_a8381649-5083-42c4-9ed2-4e92e03a6180.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4340R
Trainline PLC
06 July 2022
REMINDER OF PRODUCT INNOVATION WEBINAR EVENT
6th July 2022
As a reminder, the Company will host a webinar for investors and analysts on product innovation today, 6th July 2022 at 15.00 BST.
The webinar will include a presentation and Q&A discussion, led by Dave Price, Chief Product Officer, Steve Gooder, Product Director, and Shaun McCabe, Chief Financial Officer. The webinar will provide a deep dive into how Trainline's product innovation enhances the customer experience - a key strategic growth priority. No new material financial information will be provided.
Please register to participate by clicking the link below:
If participants want to ask a question over the phone or are unable to connect via the web, they can dial into the telephone conference call using the details below.
1. Call the appropriate participant dial-in number listed below.
2. Ask the call operator to connect to the Trainline call.
| Location | Purpose | Phone Type | Phone Number |
| United Kingdom | Participant | Local | +44 (0) 1 21 281 8004 |
| United States | Participant | Local | +1 718 7058796 |
Enquiries
For investor enquiries, Andrew Gillian [email protected]
For media enquiries, Jennifer Painter [email protected]
Brunswick Group
Simone Selzer +44 207 404 5959 / [email protected]
About Trainline:
Trainline (www.trainline.com) is the leading independent rail and coach travel platform selling rail and coach tickets to millions of travellers worldwide, enabling them to seamlessly search, book and manage their journeys all in one place via its highly rated website and mobile app. Trainline is a one-stop shop for rail and coach travel bringing together millions of routes, fares and journey times from rail and coach carriers across Europe.
This announcement includes forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Group's control and all of which are based on the Directors' current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "guidance", "believe", "expects", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positioned", "targets" or "anticipates" or the negative thereof, other variations thereon or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding the intentions, beliefs or current expectations of the Directors or the Group concerning, among other things, the results of operations, financial condition, prospects, growth, strategies, and dividend policy of the Group and the industry in which it operates. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the Group. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed, or implied in such forward-looking statements. Such forward-looking statements contained in this announcement speak only as of the date of this announcement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCKZGGNRKVGZZM